Invivyd Inc (IVVD)
$0.81
Performance
- $0.81$0.87$0.81
0.0%
Downside
Day's Volatility :7.37%
Upside
7.37%
- $0.81$5.20$0.81
0.0%
Downside
52 Weeks Volatility :84.41%
Upside
84.41%
Returns
| Period | Invivyd Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -51.83% | 0.0% |
6 Months | -78.64% | 0.0% |
1 Year | -54.01% | 0.0% |
3 Years | -98.05% | -22.3% |
Highlights
Market Capitalization | 101.5M |
Book Value | $1.18 |
Earnings Per Share (EPS) | -1.8 |
Wall Street Target Price | 8.65 |
Profit Margin | 0.0% |
Operating Margin TTM | -2175.22% |
Return On Assets TTM | -53.56% |
Return On Equity TTM | -96.56% |
Revenue TTM | 2.3M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -210.7M |
Diluted Eps TTM | -1.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.91 |
EPS Estimate Next Year | -0.32 |
EPS Estimate Current Quarter | -0.37 |
EPS Estimate Next Quarter | -0.27 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 967.9%
Technicals Summary
Sell
Neutral
Buy
Invivyd Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Invivyd Inc | -18.6% | -78.64% | -54.01% | -98.05% | -96.1% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Invivyd Inc | NA | NA | NA | -0.91 | -0.97 | -0.54 | NA | 1.18 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Invivyd Inc | Buy | $101.5M | -96.1% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Invivyd Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 91.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 167.3%
Institutional Holdings
Maverick Capital Ltd
9.85%Deep Track Capital, LP
9.17%M28 Capital Management LP
7.74%FMR Inc
7.01%BlackRock Inc
3.75%Vanguard Group Inc
3.60%
Company Information
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.
Organization | Invivyd Inc |
Employees | 94 |
CEO | Dr. Robert D. Allen Ph.D. |
Industry | Healthcare |
